1. Women 18 to 40 years of age inclusive who can give written informed consent 
2. Available for all visits and consent to follow all procedures scheduled for the study 
3. Agree to daily application of gel and monitoring as per Daily Monitored Adherence (DMA) method 
4. Healthy and self-reported sexually active 
5. HIV-negative as determined by a HIV rapid test at time of enrollment 
6. On a stable form of contraception and willing to continue on this stable method of contraception, OR, Have undergone surgical sterilisation at least 3 months prior to enrollment 
7. In the absence of the use of exogenous hormone(s), have a self-reported regular menstrual cycle defined as having a minimum of 21 days and a maximum of 36 days between menses 
8. Upon pelvic/speculum examination and colposcopy at the time of enrollment, the cervix and vagina appear normal as determined by the investigator 
9. Asymptomatic for genital infections at the time of enrollment 
10. Willing to refrain from use of vaginal products or objects within 14 days prior to enrollment and for the duration of the study 
11. Willing to answer acceptability and adherence questionnaires throughout the study 
12. Willing to refrain from participation in any other research study for the duration of this study 
13. Willing to provide adequate locator information for study retention purposes and be reachable per local standard procedures 

NCT00917891_inc_T1
Person
Women
NCT00917891_inc_T2
Value
18 to 40 years
NCT00917891_inc_T3
Person
age
NCT00917891_inc_T4
Observation
can give written informed consent
NCT00917891_inc_T8
Drug
gel
NCT00917891_inc_T9
Multiplier
daily
NCT00917891_inc_T10
Procedure
monitoring
NCT00917891_inc_T11
Condition
Healthy
NCT00917891_inc_T12
Condition
sexually active
NCT00917891_inc_T13
Observation
self-reported
NCT00917891_inc_T14
Qualifier
self-reported
NCT00917891_inc_T15
Condition
HIV-negative
NCT00917891_inc_T16
Measurement
HIV
NCT00917891_inc_T17
Value
negative
NCT00917891_inc_T18
Measurement
HIV rapid test
NCT00917891_inc_T19
Temporal
at time of enrollment
NCT00917891_inc_T20
Reference_point
time of enrollment
NCT00917891_inc_T22
Drug
exogenous hormone
NCT00917891_inc_T23
Negation
absence
NCT00917891_inc_T24
Scope
absence of the use of exogenous hormone
NCT00917891_inc_T25
Value
regular
NCT00917891_inc_T26
Measurement
menstrual cycle
NCT00917891_inc_T27
Condition
regular menstrual cycle
NCT00917891_inc_T28
Value
minimum of 21 days
NCT00917891_inc_T29
Value
maximum of 36 days
NCT00917891_inc_T30
Scope
minimum of 21 days and a maximum of 36 days
NCT00917891_inc_T31
Procedure
speculum examination
NCT00917891_inc_T32
Procedure
pelvic examination
NCT00917891_inc_T33
Procedure
colposcopy
NCT00917891_inc_T34
Temporal
at the time of enrollment
NCT00917891_inc_T35
Scope
pelvic/speculum examination and colposcopy
NCT00917891_inc_T36
Observation
vagina
NCT00917891_inc_T37
Observation
cervix
NCT00917891_inc_T38
Value
normal
NCT00917891_inc_T39
Qualifier
normal
NCT00917891_inc_T41
Scope
cervix and vagina appear normal
NCT00917891_inc_T42
Condition
genital infections
NCT00917891_inc_T43
Mood
Asymptomatic
NCT00917891_inc_T44
Temporal
at the time of enrollment
NCT00917891_inc_T45
Mood
Willing
NCT00917891_inc_T46
Drug
vaginal products
NCT00917891_inc_T47
Drug
objects vaginal
NCT00917891_inc_T48
Temporal
within 14 days prior to enrollment
NCT00917891_inc_T49
Temporal
for the duration of the study
NCT00917891_inc_T50
Reference_point
enrollment
NCT00917891_inc_T51
Reference_point
the study
NCT00917891_inc_T52
Scope
vaginal products or objects
NCT00917891_inc_T53
Observation
adherence questionnaires
NCT00917891_inc_T54
Observation
acceptability questionnaires
NCT00917891_inc_T55
Temporal
throughout the study
NCT00917891_inc_T56
Negation
refrain
NCT00917891_inc_T57
Mood
Willing
NCT00917891_inc_T58
Scope
acceptability and adherence questionnaires